Company news

Viatris Inc. news in 2022

Viatris Inc.'s news releases, calls and decks from 2022, newest first.

View company

Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors

December 28, 2022

Viatris Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference

December 22, 2022

Viatris Announces Donations Totaling $1 Million to Provide Aid Supporting Access to Healthcare, Food Security and Water Stewardship

December 13, 2022

Viatris Announces Approval of Emissions Reduction Targets by the Science Based Target initiative (SBTi)

December 13, 2022

Viatris Completes Biosimilars Transaction with Biocon Biologics

November 28, 2022

Biocon Biologics Completes Acquisition of Viatris' Global Biosimilars Business

November 28, 2022

Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences

November 17, 2022

Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent

November 9, 2022

Viatris Reports Strong Third Quarter 2022 Results

November 6, 2022

Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event

November 6, 2022

Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris

November 6, 2022

Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022

October 23, 2022

Viatris Named to Forbes' Annual List of the World's Best Employers for the Second Year in a Row

October 10, 2022

Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)

September 20, 2022

Viatris Inc. to Participate in BofA Global Research Global Healthcare Conference

September 5, 2022

Viatris Reports Strong Second Quarter 2022 Results

August 7, 2022

Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

June 30, 2022

Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

May 19, 2022

Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals

May 15, 2022

Viatris Reports Strong First-Quarter 2022 Results

May 8, 2022

Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022

April 7, 2022

Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19

March 29, 2022

Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent

March 16, 2022

Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva

March 15, 2022

Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfoli...

February 27, 2022

Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

February 3, 2022

Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease

February 2, 2022

Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend

January 5, 2022

Calls in 2022

Decks in 2022